Kollewe K, Gaul C, Gendolla A, et al. - The present study was conducted to evaluate whether real-life use of onabotulinumtoxina decreases healthcare resource utilization in individuals with chronic migraine. Researchers conducted a 2-year prospective, multicentre, non-interventional, observational study to present the real-world use of onabotulinumtoxinA in adult patients with chronic migraine (CM). This trial analyzed the impact of onabotulinumtoxinA on healthcare resource utilisation (HRU). The study enrolled 641 patients at 78 study centres across 7 countries (Germany, UK, Italy, Spain, Norway, Sweden, and Russia), 633 received ≥ 1 onabotulinumtoxinA dose, and 128 completed the 2-year study. This study’s findings illustrate that onabotulinumtoxinA treatment is correlated with reduced HRU and supports the long-term advantages correlated with the use of onabotulinumtoxinA for CM in clinical practice.